He is Dr. Haihui, returning home from 0 start-up, breaking the monopoly of high-end preparation giants!

Guide: From 0, he said: No regrets2011, the national "12th Five-Year Plan" to include biomedicine as a strategic industry, and in 2016, the "13th Five-Year Plan" will be the development of high-end preparations into the country's development planningthese new policies and initiatives not only affirmed the importance of preparation technology, especially high-end formulation technology, but also opened up a high-speed development path for the development and industrialization of high-end preparations, but also opened up a broad world for his "high-end preparation dream"he is the hero of today's medical characters - Liu FengDrLiu Feng,, Chairman and General Manager of Guangzhou Diqi Pharmaceutical Technology Co., Ltd.
from MacroMed (now BTG Healthcare), a senior scientist at Perrigo Company, to aptuit (now Catalent Solution Pharma Inc.), give up the familiar working environment and start from the beginning of the 0-year-old entrepreneurial dreamer, how can he break the monopoly of the high-end preparation giant and become the leader of high-end preparation? Recently, Pharmaceutical Intelligence Media interviewed DrLiu Feng in particular to hear about his high-end pharmaceutical preparationsdon't forget the first heart, determined to return home by "preparation dream"reporter: as a high-level overseas students, your study experience is what?liu Feng,: I received my Bachelor's and Master's degrees in Chemistry from Zhongshan University in 1985 and 1988, my Ph.Din polymer symbiosis from the Department of Chemistry, Wuhan University, in 1993, and my postdoctoral work at the Beijing Institute of Chemistry of the Chinese Academy of Sciences in 1993Molecular Composites; In 1995, he was invited by the late renowned drug probation expert and academician Professor Sung Wan Kim to work as a postdoctoral fellow in the Department of Pharmacy at the University of Utah School of Pharmacy; and in 2010 received an MBA from the Henry Black School of Business and Management at the University of Missouri, Kansas CityReporter: After graduation, which pharmaceutical companies in foreign countries have worked?Liu Feng: From 1997 to 2002, he was a senior scientist at MacroMed (now BTG Healthcare) and participated in and led the synthesis and amplification of the world's first biodegradable thermal hydrogel ReGel (Carrier)2003-2004, he was a Senior Manager at Pharmadigm Inc., where he led the development and process amplification of prescription processes for innovative drugs for the treatment of asthma, which completed Phase I/II clinical work2004-2007, Perrigo Company, then the world's largest pharmaceutical company, was a senior scientist, leading and participating in the development and industrialization of four listed products2007-2010, he was a senior manager at Aptuit Inc(acquired by Catalent Pharma Solution, the largest service company in the United States), where he led the development and industrialization of Ribavirin rapid release tablets, the development of a prescription process for a heart failure relief drug and the development and clinical batch production of a clinical batch (Phase I/II clinical) and more than a dozen clinical lysines for I, II and III clinical drugsreporter: Why give up the favorable conditions abroad, back to the domestic start high-end preparation field to explore and develop?Liu Feng: Entrepreneurship has always been a dream of mineI hope that through such a carrier, complete a technology or a series of technology through concept, research and development, industrialization to the listing and sales of such a whole process, so that people away from the pain, life extension;in fact, entrepreneurship and work is different, entrepreneurship not only need talent, need technology, but also can not be separated from the support of national policies, so-called heaven and earth to benefit people and lack of oneIn 2010, the research of new high-end formulations has become the forefront of international drug innovation, and Chinese pharmaceutical companies are facing a major juncture in the development processAt this time, I choose to return home to start a business, will be "developing and manufacturing people can afford high-quality, efficient, long-term, high-compliance of the good medicine" as the vision of the development of Diqi, and just at this time, China's pharmaceutical companies are also on the eve of major changes2011, at the 4th session of the 11th National People's Congress, the national "12th Five-Year Plan" listed biomedicine as a strategic industry,and the regulations and market policies of the pharmaceutical industry were carrying out major reforms; The new policy of the country points out the direction for the development of high-end formulation industrythe road is long, only the prospecter wins reporter: Europe and the United States standard market drug approval, with what is different from the domestic? Liu Feng, , : After 2015, the domestic drug regulations and approval process with Europe and the United States more and more in line, and CDE exchanges are becoming more and more smooth in the dosage form innovation and dosage form change, the domestic regulations and Europe and the United States still have some differences, the domestic emphasis on excellence As an example, if you change a drug taken multiple times a day to one dose a day or once every four weeks, it is clear that there is a clear advantage in compliance with the drug taken once a day or every four weeks; However, after all, medicine is also a commodity, patients will have their own preferences, whether to take tablets or capsules or dispersed tablets, should enjoy a certain choice of rights Reporter: As an expert in preparation research and development for more than 20 years, how do you see the current development of the prescription process of solid preparations and injections in China? Liu Feng, , : domestic generic drug development and production from the past market-oriented, developed to today's patient demand-oriented, in the concept of a qualitative metamorphosis, in the choice of products, dosage form selection, product production, management and verification also have a huge change, this change quickly shortenthed the domestic and foreign preparation industry technology and quality distance in the development of two types of innovative drugs, we still have a certain distance, mainly in the shortage of talent, equipment shortage and the shortage of available raw materials These problems are not very serious in the field of solid preparations, but the problems of injection, especially high-end preparations, are more prominent In order to support the development of self-developed long-acting injections and the demand of the high-end formulation market, Tics this year declared two sizes of PLGA accessories, PLGA8515 and PLGA7525, and is expected to declare PLGA5050 by the end of 2020 Tic hopes these efforts will contribute a little to the development of high-end preparations in China reporter: For the current domestic prescription process development, how do you adjust the development of enterprise layout? Liu Feng, , : The development of enterprises must be forward-looking, this forward-looking need to be through the study of industry policies, the development of the industry status quo, the future development of the industry trends and other comprehensive factors to achieve continuous technology and product innovation has been the technical basis of enterprise development, on this basis, technical services for enterprises to bring cash flow, reduce the financial risks of development at the same time enhance the technological competitiveness of enterprises, technology licensing, technical cooperation and product cooperation, listing holders are the basis for sustainable development of enterprises, the above three rely on each other, into a corner around the development of high-end preparations, Tics to build six technology platforms with independent intellectual property rights, targeting nanotechnology platform, long-acting formulation technology platform, polyethyl glycolization technology platform, slow-controlled release preparation technology platform, high-end accessories technology platform; to play the advantages of talent, quality survival reporter: three-fifths of your management team are returning talent, you think the pharmaceutical companies how to lay out talent echelon? Liu Feng, , : The introduction of talent is one of the effective means of rapid development of pharmaceutical companies, but also a common means of many pharmaceutical companies However, if there is no corresponding technical talent layout, no technology and product layout, the introduction of talent, can not let talent do their best, which not only wastes talent, but also may have a negative impact therefore, the layout of enterprises not only introduced how many senior talents, but also the construction of corporate culture, values, the construction of the system, only the environment construction is good, the introduction of talent left, its advantages can play out, the layout of enterprises can be achieved Reporter: In your opinion, how to deal with the commodity properties of drugs? Liu Feng, , : There is no doubt that the development of drugs must be patient-centered But medicine is also a commodity after all, since it is a commodity has the characteristics of the commodity Therefore, in the process of developing different dosage forms of drugs, we should not only emphasize clinical advantages, but also encourage pharmaceutical companies to develop dosage forms that patients are willing to accept on the basis of ensuring efficacy and quality, such as tablets, capsules, oral tablets, dispersed tablets, oral fluids and so on, to meet the needs of different patients in the belt procurement, generic drug consistency evaluation and other national policies in the environment, drug companies will be more and more intense competition It is hoped that the medical people can not forget the first heart, the development and manufacture of people can afford high-quality, efficient, long-acting, high compliance of good medicine, China can also walk in the forefront of international innovative preparations, especially high-end preparations Expert sq : Dr Liu Feng, Chairman and General Manager of Guangzhou Diqi Pharmaceutical Technology Co., Ltd., Vice Chairman of the 17th Board of directors of the Professional Committee of Pharmaceutical Preparations of Guangdong Pharmaceutical Society, Deputy Chairman of the First Board of Directors of the Professional Committee of the Guangdong Pharmaceutical Society, Special "Pharmaceutical Registration Review Expert" of Guangdong Province Food and Drug Supervision and Administration Review And Certification Center, Guangdong Provincial Review Of Science and Technology Experts he leads and participates in the development and industrialization of prescription processes for a number of listed and researched categories i, II new and generic drugs, including: oral reactive agents, injections, oral slow-release agents, gel formulations, targeted nanoformulationies, microsphere preparations, implants and gels .